Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069135 | 0.86 | MTNR1A (0.62) | AOC3L3MBTL1MTNR1AMTNR1BTDP1 | |
| SCHEMBL2082456 | 0.86 | MTNR1A (0.66) | AOC3L3MBTL1MTNR1AMTNR1BCHRM2 | |
| SCHEMBL7634454 | 0.85 | AOC3 (0.66) | AOC3L3MBTL1MTNR1AMTNR1BTDP1 | |
| SCHEMBL1230545 | 0.84 | AOC3 (0.54) | AOC3L3MBTL1MTNR1AMTNR1BTDP1 | |
| SCHEMBL27586522 | 0.83 | MTNR1A (0.52) | AOC3L3MBTL1MTNR1AMTNR1BTDP1 | |
| SCHEMBL13997816 | 0.82 | AOC3 (0.59) | AOC3L3MBTL1MTNR1AMTNR1BTDP1 | |
| SCHEMBL16363885 | 0.82 | AOC3 (0.59) | AOC3L3MBTL1MTNR1AMTNR1BTDP1 | |
| SCHEMBL4443866 | 0.82 | AOC3 (0.55) | AOC3L3MBTL1MTNR1AMTNR1BTDP1 | |
| SCHEMBL22953181 | 0.81 | AOC3 (0.74) | AOC3L3MBTL1TDP1CHRM2CHRM1 | |
| SCHEMBL3443108 | 0.81 | AOC3 (0.74) | AOC3L3MBTL1TDP1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | AOC3 4778/4885L3MBTL1 1699/4885MTNR1A 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.